However in 2020, she received a life-changing cystic fibrosis drug called Kaftrio, which transformed her life and drastically improved her health. Since then she has returned to full-time work, is in ...

(RTTNews) - Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved a label expansion for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in ...

-Approximately 4,000 people living with CF in the European Union are newly eligible for a medicine that treats the underlying cause of their disease for the first time- Vertex will continue to ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a combination regimen with ivacaftor for the treatment of ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio. GlobalData provides trusted ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

"We are pleased that the European Commission has broadened the KAFTRIO indication to include all CF patients 2 years and older who have at least one non-class I mutation, ensuring that even more ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO ® (ivacaftor ...

“We are pleased that the European Commission has broadened the KAFTRIO indication to include all CF patients 2 years and older who have at least one non-class I mutation, ensuring that even more ...